human chronic myelogenous leukemia cell line k562  (ATCC)

Journal: Biomedicines

Article Title: Antibody-Mediated In Vitro Activation and Expansion of Blood Donor-Derived Natural Killer Cells with Transient Anti-Tumor Efficacy

doi: 10.3390/biomedicines13122934

Figure Lengend Snippet: SNK cells exhibited enhanced cytotoxicity and effector molecule secretion in vitro (n = 3 donors). ( A ) Representative images depicting the cytotoxic effects of SNK and PBNK cells against HK-1, DU145, and K562 tumor cells after 6 h of co-culture. ( B ) Cytotoxicity was quantified at various E:T ratios using luciferase-based assays (for the other two donors of SNK against tumors, see also ). ( C ) Mean cytotoxicity against all three tumor cells, determined by luminescence. ( D , E ) Concentrations of IFN-γ ( D ) and Gzm B ( E ) in the co-culture supernatants were quantified by ELISA. Data are presented as mean ± SEM. Statistical analysis was performed using Student’s t test. Significant differences are indicated as * p < 0.05, ** p < 0.01, and *** p < 0.001; ns = not significant.

Article Snippet: Human nasopharyngeal carcinoma cell line HK-1 (YC-C095, Ubigene, Cambridge, MA, USA), human prostate cancer cell line DU145 (HTB-81, ATCC, Manassas, VA, USA), and chronic myelogenous leukemia cell line K562 (CCL-243, ATCC, Manassas, VA, USA) were cultured in complete RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA) at 37 °C in a humidified atmosphere containing 5% CO 2 .

Techniques: In Vitro, Co-Culture Assay, Luciferase, Enzyme-linked Immunosorbent Assay

Journal: Biomedicines

Article Title: Antibody-Mediated In Vitro Activation and Expansion of Blood Donor-Derived Natural Killer Cells with Transient Anti-Tumor Efficacy

doi: 10.3390/biomedicines13122934

Figure Lengend Snippet: SNK cells exhibited enhanced cytotoxicity against tumor cells in vivo. ( A ) NSG mice were intravenously injected with 1 × 10 6 K562-Luc cells through the tail vein. On day 3, mice were intravenously administered SNK cells at doses of 2 × 10 7 , 4 × 10 7 , or 8 × 10 7 cells. Tumor burden was monitored on days 3, 10, and 17 using bioluminescence imaging. ( B ) Representative bioluminescence images showing tumor progression over time. ( C ) Kaplan–Meier survival curves were generated, and statistical significance was determined using the log-rank test (* p < 0.05; ns = not significant), with a large effect size (Hazard Ratio = 2.59). ( D ) The body weights of mice were measured post-K562 cell inoculation at the indicated time points. The percentage of SNK cells (CD56 + CD3 − ) was determined by flow cytometry in the peripheral blood (PB, ( E , F )) and spleen ( G ) of mice post-SNK cell infusion.

Article Snippet: Human nasopharyngeal carcinoma cell line HK-1 (YC-C095, Ubigene, Cambridge, MA, USA), human prostate cancer cell line DU145 (HTB-81, ATCC, Manassas, VA, USA), and chronic myelogenous leukemia cell line K562 (CCL-243, ATCC, Manassas, VA, USA) were cultured in complete RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA) at 37 °C in a humidified atmosphere containing 5% CO 2 .

Techniques: In Vivo, Injection, Imaging, Generated, Flow Cytometry